US expects to start H1N1 vaccinations with 45 million doses
This article was originally published in Scrip
The US government expects to begin a vaccination campaign against the novel influenza A(H1N1) virus in mid-October with approximately 45 million doses. 20 million additional doses of vaccine will become available each week thereafter until the supply reaches the 195 million doses that federal authorities have under contract, the health and human services (HHS) department said.
You may also be interested in...
Advisory committee votes 24-2 against approval of Intellipharmaceutics’ Aximris XR due to concerns the extended-release oxycodone formulation may be more susceptible to intranasal abuse than existing products; Esteve fares better with its tramadol/celecoxib combination, securing a tie vote on approval for acute pain.
Although abuse by intravenous route is expected to be deterred compared to immediate-release oxycodone, neither nasal nor oral abuse deterrence was demonstrated in two new human abuse potential studies, agency concludes; product has a new formulation and a new name, Aximris XR, since a 2017 AdComm.
Agency’s briefing document for 15 January review of the fixed-dose product combining an opioid and nonsteroidal anti-inflammatory reflects application of opioid benefit/risk framework described in June draft guidance.